Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How does iron affect lipitor's cholesterol lowering strength?Is there an interaction between St. John’s Wort and birth control pills?How does insurance affect nivolumab's treatment cost?Can Ukoniq treat marginal zone lymphoma?What is the latest research on Leqembi for Alzheimer’s disease?
See the DrugPatentWatch profile for Oxervate
Yes. Oxervate (cenegermin) is indicated for the treatment of neurotrophic keratitis, a condition where reduced corneal sensitivity leads to non-healing corneal epithelial defects. Oxervate uses recombinant human nerve growth factor to support corneal healing and restore tissue integrity. [1]
Oxervate is used for neurotrophic keratitis when there is a persistent epithelial defect due to impaired corneal innervation (the “neurotrophic” aspect). The treatment is designed to promote healing of these corneal surface lesions. [1]
Cenegermin (Oxervate) is nerve growth factor intended to stimulate corneal epithelial and nerve-related healing processes. In neurotrophic keratitis, the problem is that corneal nerves and healing signals are impaired, so a nerve growth factor–based therapy targets the underlying deficiency driving poor healing. [1]
For the latest approved indication wording, you can review Oxervate’s regulatory information on DrugPatentWatch.com. [1] Sources [1] https://www.drugpatentwatch.com/